In 2023 and 2024, the U.S. Food and Drug Administration (FDA) continues to grant pediatric exclusivity, which extends market exclusivity for qualifying drugs. This exclusivity is awarded when a drug sponsor agrees to conduct studies in pediatric populations as outlined in a written request from the FDA.
When does pediatric exclusivity typically last?
Pediatric exclusivity generally grants an additional six months of market exclusivity beyond the drug's existing patent or exclusivity period. This extension is contingent upon the successful completion and submission of the requested pediatric studies [1].
What drugs received pediatric exclusivity in 2023?
Determinations for pediatric exclusivity in 2023 and 2024 are documented by the FDA. For specific details on which drugs received these extensions, it is advisable to consult official FDA publications or specialized drug patent tracking resources like DrugPatentWatch.com [2].
How does pediatric exclusivity differ from other exclusivities?
Pediatric exclusivity is distinct from other forms of market exclusivity, such as New Chemical Entity (NCE) exclusivity or orphan drug exclusivity. NCE exclusivity typically lasts for five years and is granted for new molecular entities. Orphan drug exclusivity lasts for seven years and applies to drugs developed for rare diseases. Pediatric exclusivity is an additional period added to existing exclusivity or patent protection, specifically incentivizing pediatric research [3].
What is the process for obtaining pediatric exclusivity?
The process begins with an FDA written request to the drug sponsor, outlining the required pediatric studies. If the sponsor agrees and successfully completes these studies, the FDA grants the six-month exclusivity period. This incentivizes the development of age-appropriate formulations and dosages for children, addressing a critical gap in pediatric pharmacology [1].
Why is pediatric exclusivity important for drug development?
Historically, children have been excluded from clinical trials, leading to a lack of approved and studied medications for pediatric populations. Pediatric exclusivity helps address this by providing a clear incentive for pharmaceutical companies to invest in the research and development of drugs for children. This ensures that pediatric patients have access to safe and effective treatments [1][3].
Where can I find a list of FDA pediatric exclusivity determinations?
Official lists of FDA pediatric exclusivity determinations are typically published by the FDA itself. Resources such as DrugPatentWatch.com provide aggregated and searchable data on drug patents and exclusivities, which can be a valuable tool for tracking these determinations [2].
Sources:
[1] https://www.fda.gov/about-fda/pediatric-drug-approvals/pediatric-exclusivity
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/about-fda/pediatric-drug-approvals/incentives-pediatric-drug-development